Superior Planning, LLC’s Monopar Therapeutics MNPR Stock Holding History

Superior Planning, LLC’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.35K	Buy	+42	New	+$4.5K	﹤0.01%	1362

Other funds holding MNPR

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Superior Planning, LLC's MNPR Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Monopar Therapeutics (MNPR) in Q3 2026: 42 shares worth $3.35K. The stake represents ﹤0.01% of the portfolio and ranks #1362 among its holdings.

43 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

Superior Planning, LLC held 42 shares of Monopar Therapeutics worth $3.35K as of Q3 2026.
Monopar Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Monopar Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1362 holding.
43 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.